cystic fibrosis

September 14, 2020September 14, 2020

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

cystic fibrosis, News

Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is safe for use in children with cystic fibrosis (CF) as young as age 6, data from a global Phase 3 clinical trial show. Based ... Read more

September 10, 2020September 10, 2020

Aridis, FDA Agree to Simplify AR-501 Trial Design Based on Positive Safety Data

cystic fibrosis, News

The U.S. Food and Drug Administration (FDA) has agreed to simplify Aridis Pharmaceuticals‘ planned Phase 2 trial of AR-501, an investigational inhaled treatment for chronic lung infections in patients with cystic ... Read more

September 9, 2020September 9, 2020

Savara Closing Trial of Molgradex in Treating NTM Lung Infections in CF Patients

cystic fibrosis, News

Savara Pharmaceuticals is stopping its Phase 2a exploratory clinical study of Molgradex (molgramostim nebulizer solution) to treat nontuberculous mycobacterial (NTM) lung infection in people with cystic fibrosis (CF), the company announced in a press release. The decision ... Read more

September 4, 2020September 4, 2020

CF Patients With Poorer Lung Function at Greater Risk of Premature or Smaller Baby, Study Shows

cystic fibrosis, News

Pregnancy is generally safe for both women with cystic fibrosis (CF) and their child, but those with poorer lung function are at greater risk of having a premature or smaller baby, ... Read more

September 3, 2020September 3, 2020

New Technology Could Improve Detection of Biomarkers for CF, Other Diseases

cystic fibrosis, News

A new strategy for detecting very small concentrations of specific molecules could allow for better diagnosis and management of a variety of diseases, including cystic fibrosis (CF). The method ... Read more

September 2, 2020September 2, 2020

Vertex Seeks to Expand FDA Approval of CFTR Modulators to Include More Mutations

cystic fibrosis, News

The U.S. Food and Drug Administration (FDA) is reviewing applications from Vertex Pharmaceuticals to expand the approval for three of the company’s cystic fibrosis (CF) therapies: Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ... Read more

September 1, 2020September 1, 2020

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

cystic fibrosis, News

ContraFect will receive funding from the Cystic Fibrosis Foundation to conduct preclinical research about the potential of direct lytic agents, an alternative to conventional antibiotics, to treat lung infections caused by ... Read more

August 31, 2020August 31, 2020

Same But Different Photo Contest Celebrates People With Rare Diseases

cystic fibrosis, News, syndicated

Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography competition to raise awareness for rare diseases. Under the theme ... Read more

August 31, 2020August 31, 2020

UK Registry Finds CF Community Living Longer, Becoming More Diverse

cystic fibrosis, News

People with cystic fibrosis (CF) in the U.K. have grown more numerous, older, and more diverse, according to the U.K. Cystic Fibrosis Registry’s annual data report for 2019. The ... Read more

August 28, 2020August 28, 2020

Trikafta’s Arrival in Canada Could Cut CF Deaths by 15% Over 10 Years, Study Suggests

cystic fibrosis, News

If Trikafta — Vertex Pharmaceuticals’ next-generation triple combination cystic fibrosis (CF) therapy — were to be available in Canada next year, the median age of CF patients could rise by 9.2 ... Read more